To date, PD-L1 expression represents the most useful predictive biomarker to determine immunotherapy efficacy in thyroid tumors [168,174,175], with PD-L1 positivity ranging from 6.1 to 82.5% in PTCs and from 22.2% to 81.2% in ATCs [176]. The gene discussed is CD274; the disease is Ehlers-Danlos syndrome, musculocontractural type.